Trials / Unknown
UnknownNCT06232278
Long-term Results of Percutaneous Left Atrial Closure at Brest University Hospital (CLAPOT)
Long-term Results of Percutaneous Left Atrial Closure at Brest University Hospital.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (estimated)
- Sponsor
- University Hospital, Brest · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Atrial Fibrillation represents an important risk of cardioembolic stroke. In more than 90% of cases, thrombus originate in the left atrial appendage. Therefore guidelines recommend the anticoagulation of patients with atrial fibrillation and a significant cardioembolic risk, predicted by the CHA2DS2VASc score. However, serious bleeding complications may definitively contraindicate the use of anticoagulants. For those patients, percutaneous Left Atrial Appendage Occlusion (LAAO) has became a recommended alternative to prevent the thrombus formation and reduce the risk of cardioembolic events. In the CHU of Brest, more than 120 patients have been treated with LAAO for the last 8 years with two different occluder devices : WATCHMAN®, Boston Scientifc and AMPLATZER Amulet®, Abbott Laboratories. This retrospective longitudinal observational study named CLAPOT (CHU of Brest' Left Atrial Appendage Percutaneous Occlusion Treatment) aims to evaluate the long term results of this procedure for effectiveness and safety and to compare the results between the two devices (Watchman and Amplatzer).
Conditions
- Atrial Fibrillation
- Cardioembolic Stroke
- Left Atrial Appendage Thrombosis
- Anticoagulant-induced Bleeding
Timeline
- Start date
- 2024-02-01
- Primary completion
- 2024-05-31
- Completion
- 2025-05-31
- First posted
- 2024-01-30
- Last updated
- 2024-08-09
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06232278. Inclusion in this directory is not an endorsement.